

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (currently amended) A therapeutic agent for glaucoma comprising a combination of pharmaceutically effective amounts of (i) a Rho kinase inhibitor and (ii) a β -blocker, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide.

Claim 2. (currently amended) A therapeutic agent for glaucoma ~~characterized in that it~~ which comprises a combination of pharmaceutically effective amounts of (i) a Rho kinase inhibitor and (ii) a β -blocker, and they complement and/or enhance their actions with respect to each other, wherein the Rho kinase inhibitor is (R)-(+)-N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide.

Claim 3. (canceled)

Claim 4. (original) The therapeutic agent for glaucoma as claimed in claim 1 or 2, wherein the β -blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

Claim 5. (withdrawn) A method of treating glaucoma comprising administering effective amounts of a Rho kinase inhibitor in combination with a β -blocker to a patient.

Claim 6. (withdrawn-currently amended) A method of treating glaucoma ~~characterized by~~ comprising administering effective amounts of a Rho kinase inhibitor in combination with a β -blocker to a patient, thereby they ~~complementing~~ complement and/or ~~enhancing~~ enhance their actions with respect to each other.

Claim 7. (withdrawn) The method of treating glaucoma as claimed in claim 5 or 6, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexanecarboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)-homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 8. (withdrawn) The method of treating glaucoma as claimed in claim 5 or 6, wherein the β -blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.

Claim 9. (withdrawn) Use of a combination of a Rho kinase inhibitor and a β -blocker in the manufacture of a therapeutic agent for glaucoma.

Claim 10. (withdrawn) Use of a combination of a Rho kinase inhibitor and a β -blocker in the manufacture of a therapeutic agent for glaucoma, characterized in that their actions are complemented and/or enhanced each other.

Claim 11. (withdrawn) The use of the combination of the Rho kinase inhibitor and the β -blocker as claimed in claim 9 or 10, wherein the Rho kinase inhibitor is (R)-trans-N-(pyridin-4-yl)-4-(1-aminoethyl)cyclohexane-carboxamide, (R)-(+) -N-(1H-pyrrolo[2,3-b]pyridin-4-yl)-4-(1-aminoethyl)benzamide, 1-(5-isoquinolinesulfonyl)homopiperazine or 1-(5-isoquinolinesulfonyl)-2-methylpiperazine.

Claim 12. (withdrawn) The use of the combination of the Rho kinase inhibitor and the β -blocker as claimed in claim 9 or 10, wherein the β -blocker is timolol, befunolol, carteolol, nipradilol, betaxolol, levobunolol or metipranolol.